German reimbursement agreed for Santhera’s Agamree

13 February 2025

Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharma focused on rare diseases, has announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement for Agamreee (vamorolone) to treat Duchenne muscular dystrophy (DMD).

According to Santhera, this agreement, which ensures that patients across Germany can benefit from this innovative therapy, reflects the company’s commitment to ensuring broad patient access while supporting sustainable healthcare outcomes.

The agreed ex-factory price is 3,612.50 euros ($3,763) per 100ml bottle, translating into approximately 52,000 euros per year for an average patient when considering required rebates, patient weight and dosing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK